Five of the company’s vaccines are currently in Phase III.
At its Vaccines Day event, Moderna revealed various clinical and program updates concerning its mRNA pipeline. The company’s vaccine portfolio features 28 vaccines that combat latent, respiratory, and other pathogens.1
When it comes to virus-causing infections, all of these are currently undergoing clinical trials. A latent virus often does not cause obvious symptoms—existing in a resting state—which is a main quality in the Herpesviridae family. These viruses include:
There are also ongoing trials for herpes simplex virus (HSV)—the main cause of genital herpes— and Varicella-Zoster virus (VZV)—also known as shingles—which are planning to begin Phase I/II trials and planning for Phase III respectively.
When it comes to enteric viruses, such as norovirus, it is highly contagious and a leading cause of diarrheal disease worldwide, as it is attributed to 18% of all acute gastroenteritis (AGE), and approximately 200,000 deaths annually. There is currently a randomized, observer-blind, placebo-controlled Phase I trial that tested the safety, reactogenicity and immunogenicity of trivalent (mRNA-1403) and pentavalent (mRNA-1405) norovirus vaccine candidates in 664 participants in both the 18-49 and 60-80 age ranges in the United States. Initial analysis suggested one dose of mRNA-1403 produces a “robust immune response,” and as result, a Phase III trial could be in the works.
Moderna also has a respiratory portfolio, which includes (but is not limited to COVID-19; Respiratory Syncytial Virus or RSV; and the flu.
"Our mRNA platform continues a remarkable track record across our broad vaccine portfolio. Today, we are excited to share that four vaccines in our pipeline have achieved successful clinical readouts across our respiratory, latent and other virus franchises," noted Stéphane Bancel, Moderna’s CEO. "With five vaccines in Phase III, and three more moving toward Phase III, we have built a very large and diverse portfolio addressing significant unmet medical needs. We are focused on execution to further build momentum across our pipeline and business, and to deliver for patients who are impacted by these infectious diseases.”
Reference
1. Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials. Moderna. News release. March 27, 2024. Accessed March 28, 2024. https://investors.modernatx.com/news/news-details/2024/Moderna-Advances-Multiple-Vaccine-Programs-to-Late-Stage-Clinical-Trials/default.aspx
Is Compounding the Answer to the Semaglutide Shortage? Experts Weigh In
October 30th 2024In this Q&A, Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding discuss the challenges faced by patients and healthcare providers due to drug shortages, particularly for semaglutide and other medications.